SION: AscenSION CF will test SION-451 + SION-2222 as a novel dual therapy for cystic fibrosis
Post hoc analysis of the PreciSION CF Phase IIa trial revealed confounding due to non-adherence and lower Trikafta exposures, supporting a shift to the SION-451 + SION-2222 dual combination. The upcoming AscenSION CF trial will test this regimen as a standalone therapy, aiming to address unmet need…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.